GBT - GBT STOCK NEWS

Global Blood Therapeutics (GBT) has announced the opening of proposals for its third annual Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program. This year, GBT is doubling the total funding available, providing 10 grants of up to $50,000 each for community-based organizations focused on improving access to care for individuals with sickle cell disease (SCD). The program's priorities now include addressing racial equity and COVID-19 vaccine awareness among the SCD community. Proposals are accepted until April 23, 2021.

Global Blood Therapeutics (GBT) will participate in the H.C. Wainwright Global Life Sciences Conference scheduled for March 9, 2021. A presentation by the company's president and CEO, Ted W. Love, M.D., is set to be available at 7:00 a.m. ET. The presentation will be accessible on GBT's website for one month post-event. GBT is dedicated to developing treatments for sickle cell disease and has introduced Oxbryta, the first FDA-approved treatment targeting sickle hemoglobin polymerization.

Global Blood Therapeutics (GBT) reported Q4 2020 net revenues of $41.3 million and total annual sales of $123.8 million, a significant increase from $2.1 million in 2019. Oxbryta has gained traction with over 950 new prescriptions in Q4, despite pandemic challenges. GBT aims to strengthen access and education around Oxbryta, while advancing its pipeline programs, inclacumab and GBT601, with pivotal trials planned for 2021. The company ended 2020 with $560.9 million in cash and equivalents, indicating a solid financial position for further investments.

Global Blood Therapeutics (GBT) will engage in virtual fireside chats at two investor conferences: the SVB Leerink 10th Annual Global Healthcare Conference on February 26 at 2:20 p.m. ET and the Cowen 41st Annual Health Care Conference on March 1 at 11:40 a.m. ET. CEO Ted W. Love will also participate in a panel on Non-Malignant Hematology on March 1 at 2:40 p.m. ET. The events will be available live on GBT’s website, with replays archived for a month after each conference.

GBT focuses on treatments for sickle cell disease, having developed Oxbryta®, the first FDA-approved treatment for this condition.

Global Blood Therapeutics (GBT) will release its fourth quarter and full year 2020 financial results on February 24, 2021, after the market closes. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results along with a general business update. Interested parties can listen in through a live audio webcast via GBT’s website. GBT focuses on treatments for sickle cell disease, including its FDA-approved drug Oxbryta and ongoing pipeline efforts with inclacumab and GBT021601.

Global Blood Therapeutics (GBT) announced on February 1, 2021, the granting of 103,450 restricted stock units to 14 new employees. This issuance is part of GBT's Amended and Restated 2017 Inducement Equity Plan and follows NASDAQ regulations for employee inducement. The plan aims to attract and retain talent in the biopharmaceutical sector, particularly in developing treatments for sickle cell disease. GBT continues its commitment to innovate therapies like Oxbryta and other pipeline candidates.

Global Blood Therapeutics (GBT) announced the launch of an Expanded Access Protocol (EAP) for its sickle cell disease treatment, Oxbryta® (voxelotor), for pediatric patients aged 4-11 who lack treatment options. Enrollment began in January 2021. The EAP aims to provide access to Oxbryta prior to formal approval for this age group, reinforcing GBT's commitment to improving patient access. Oxbryta, currently approved for ages 12 and older, works by inhibiting hemoglobin polymerization, addressing significant medical needs in SCD.

Global Blood Therapeutics (GBT) announced the European Medicines Agency (EMA) has validated its Marketing Authorization Application for Oxbryta^® (voxelotor) tablets, initiating a standard review process. GBT seeks approval for treating hemolytic anemia in sickle cell disease (SCD) patients aged 12 and older. Oxbryta, a first-in-class therapy, directly inhibits hemoglobin polymerization, addressing SCD's root causes. The application is based on Phase 3 and Phase 2 studies demonstrating significant hemoglobin improvements with favorable safety profiles.

Global Blood Therapeutics (GBT) announced on January 1, 2021, the granting of restricted stock units totaling 27,500 shares to six new employees. This action aligns with GBT’s Amended and Restated 2017 Inducement Equity Plan, ensuring compliance with NASDAQ Listing Rule 5635(c)(4). The company aims to strengthen its contributions to the treatment of sickle cell disease by investing in its workforce.